Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

AZ pays $100mm up front for rights to Rigel's RA candidate; rights later returned

Executive Summary

AstraZeneca PLC will pay $100mm up front for exclusive worldwide development, manufacturing, and commercialization rights to Rigel's (small molecules for inflammation, autoimmune diseases, and metabolic conditions) fostamatinib (R788), a spleen tyrosine kinase (Syk) inhibitor that has completed Phase II trials for rheumatoid arthritis in patients who have not responded to prior drug therapies.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information

Related Companies

Advertisement
UsernamePublicRestriction

Register